Tempest Therapeutics Inc (TPST) — Titan Protect Analysis

TPST

Tempest Therapeutics Inc

Healthcare · ·

$1.27

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$19M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.03

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-203.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.00

+766% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Tempest Therapeutics Inc

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating va

https://www.tempesttx.com

Country: United States Employees: 4 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-1.265

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.1643

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.855

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-83.1%

Historical annualised return based on price data

Max Drawdown

-97.1%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-1.69

Very low correlation to market moves

52W High

$12.23

90% below the year high

52W Low

$1.25

2% above the year low

Avg Volume

205,785

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-5.70

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

122.09

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-17,585,750

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-26,262,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$11.00

Target Median

$11.00

Target Low

$11.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go